

YTHDF3-mediated m6A Modification Facilitates Osteosarcoma Progression through the FSP1-CoQ10-NAD(P)H Axis to Suppress Ferroptosis

Keywords

Ferroptosis, Osteosarcoma, m6A modification, YTHDF3, FSP1

Abstract

Introduction

Osteosarcoma (OS) remains a formidable malignancy, characterized by its relentless nature and limited therapeutic interventions. YTHDF3, a key reader protein recognizing m6A-modified mRNAs, has attracted considerable attention due to its prominent role in cancer biology. This study embarks on an exploration of the intricate interplay between YTHDF3, a vital RNA modification reader protein, m6A RNA modification, and the FSP1-CoQ10-NADPH metabolic pathway in the pathogenesis of OS.

Material and methods

Firstly, we procured tissue specimens and corresponding non-cancerous tissues from 10 OS patients and cultured OS cell lines. Then, we established a ferroptosis model in OS cells through treatment with RSL3 to reveal the relation between YTHDF3 and ferroptosis.

Results

Clinical evaluation of OS samples revealed a notable upsurge in the expression of YTHDF3 and the concurrent overexpression of ferroptosis-related proteins. In vitro experiments suggested that YTHDF3 potentially facilitated FSP1 mRNA translation through an m6A-dependent mechanism, subsequently inhibiting ferroptosis via the FSP1-CoQ10-NADPH pathway, thereby promoting OS progression.

Conclusions

These compelling findings underscore the promise of targeting the YTHDF3-FSP1 axis as an innovative and potentially transformative therapeutic strategy for the treatment of OS. This study not only enhances our understanding of ferroptosis regulation but also sheds light on the significance of YTHDF3 and FSP1 as potential targets for therapeutic intervention in OS, offering new prospects for cancer treatment strategies.

YTHDF3-mediated m6A Modification Facilitates Osteosarcoma Progression through the FSP1-CoQ10-NAD(P)H Axis to Suppress Ferroptosis

Wei Liu^{1 2 #}, Qingning Li^{3 #}, Nan Zhu^{1 2}, Shuo Zhang^{1 2}, Juehua Jing^{1 2*}, Junfeng Zhan^{1 2*}

1 Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.

2 Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.

3 Emergency Department, Anhui No.2 Provincial People's Hospital, Hefei 230041, China.

#This work is the result of a collaborative effort by these writers.

*Corresponding author: Zhanjunfeng0901@163.com and jjhhu@sina.com

Running head: YTHDF3 inhibits ferroptosis by FSP1-CoQ10-NAD(P)H in OS

Preprint

Abstract

Osteosarcoma (OS) remains a formidable malignancy, characterized by its relentless nature and limited therapeutic interventions. YTHDF3, a key reader protein recognizing m6A-modified mRNAs, has attracted considerable attention due to its prominent role in cancer biology. This study embarks on an exploration of the intricate interplay between YTHDF3, a vital RNA modification reader protein, m6A RNA modification, and the FSP1-CoQ10-NADPH metabolic pathway in the pathogenesis of OS. Firstly, we procured tissue specimens and corresponding non-cancerous tissues from 10 OS patients and cultured OS cell lines. Then, we established a ferroptosis model in OS cells through treatment with RSL3 to reveal the relation between YTHDF3 and ferroptosis. Clinical evaluation of OS samples revealed a notable upsurge in the expression of YTHDF3 and the concurrent overexpression of ferroptosis-related proteins. *In vitro* experiments suggested that YTHDF3 potentially facilitated FSP1 mRNA translation through an m6A-dependent mechanism, subsequently inhibiting ferroptosis via the FSP1-CoQ10-NADPH pathway, thereby promoting OS progression. These compelling findings underscore the promise of targeting the YTHDF3-FSP1 axis as an innovative and potentially transformative therapeutic strategy for the treatment of OS. This study not only enhances our understanding of ferroptosis regulation but also sheds light on the significance of YTHDF3 and FSP1 as potential targets for therapeutic intervention in OS, offering new prospects for cancer treatment strategies.

Keywords: Osteosarcoma, YTHDF3, m6A modification, FSP1, Ferroptosis

Introduction

Osteosarcoma (OS), originating from primitive mesenchymal cells, represents a primary malignant musculoskeletal neoplasm. Due to its pronounced malignancy, early metastasis, intrinsic resistance, high disability rate, elevated mortality, and exceedingly poor prognosis, OS presents a disheartening therapeutic outlook[1, 2]. Comprehensive elucidation of its pathogenesis is urgently warranted, offering novel avenues for the progression of innovative therapies. In recent times, attention has turned to ferroptosis, a unique form of iron-dependent regulated cell death, distinct from classical modes such as necrosis, apoptosis, and autophagy, as a potential avenue of interest[3, 4]. Emerging findings have spotlighted Apoptosis-Inducing Factor Mitochondria-Associated 2 (AIFM2), namely Ferroptosis Suppressor Protein 1 (FSP1) or Programmed Cell Death Protein 3 (PRG3), as an endogenous inhibitor of ferroptosis, capable of impeding phospholipid peroxidation and cellular iron-driven demise via the FSP1-CoQ10-NADPH pathway[5-7]. Meanwhile, extracellular vesicle-derived miR-4443 modulates ferroptosis by targeting METTL3 in non-small cell lung cancer (NSCLC) to suppress FSP1 m6A modification[8]. However, the involvement of FSP1 in OS remains uncharted territory in current literature.

N6-methyladenosine (m6A) stands as the most prevalent and ubiquitous mRNA modification, exercising pivotal roles and functionalities throughout a spectrum of biological processes. An accumulating body of evidence underscores the participation of m6A regulatory factors in various cancers, exerting significant roles in tumor cell proliferation and metastasis[9-11]. Reports have highlighted ALKBH5, a pivotal RNA demethylase, which, via an m6A-YTHDF2-dependent mechanism, orchestrates STAT3 activity, consequently impacting OS proliferation and oncogenicity[12]. Likewise, METTL14, serving as an m6A RNA methyltransferase, contributes to OS progression and all-trans-retinoic acid resistance by modulating MN1 stability and translation efficiency[13]. Consequently, the targeting of specific gene m6A modifications emerges as a promising strategy for cancer therapy.

The YTH domain family protein 3 (YTHDF3) holds a pivotal role in governing the translation of mRNA modified by N6-methyladenosine (m6A), and it exerts its regulatory influence on the degradation of methylated mRNA through an m6A methylation-dependent pathway[14]. YTHDF3 has been evidenced to contribute to the progression of several tumor types, including gastric[15] and colorectal cancers[16]. Nevertheless, the functional implications of YTHDF3 during ferroptosis in cancer cells remain uncharted. In this study, we delve into the role of YTHDF3 in OS cell death and evaluate its regulatory effect on FSP1 m6A modification. Our findings furnish novel evidence for the prospective therapeutic targeting of YTHDF3 in the management of OS.

Materials and Methods

Tissue collection

From September 2017 to December 2020, we collected pathological specimens from OS patients at The Second Hospital Affiliated with Anhui Medical University. Additionally, adjacent non-cancerous tissues were obtained after excluding patients with coexisting malignancies, cardiovascular or psychiatric disorders. We successfully procured OS tissue specimens and corresponding non-cancerous tissues from 10 patients. Pathological assessment by two pathologists confirmed the diagnosis of OS. For preservation, tissue samples were immediately frozen in liquid nitrogen and kept at -80°C . Ethics Committee of this hospital approved the study in accordance with ethical standards. The informed consent was acquired from all patients and their families, ensuring their understanding of the study's purpose and procedures.

Cell culture and treatment

The Chinese Academy of Sciences' Cell Bank (Shanghai, China) provided the OS cell lines U2OS and Mg-63. 10% fetal bovine serum was added to Dulbecco's Modified Eagle Medium (DMEM), and the cells were grown in this medium while being kept at 37°C and 5% CO_2 . To induce iron-dependent cell death, cells were treated with RSL3 (Sigma). An equal volume of dimethyl sulfoxide (DMSO) without the drug was put into the control cells. YTHDF3-sh, YTHDF3-OE, FSP1-sh, and FSP1-OE plasmids were obtained from GeneChem (Shanghai, China). For 48 hours, oligonucleotides were combined with Lipofectamine 2000. Subsequently, cells were applied for subsequent study.

RNA extraction and cDNA synthesis

Total RNA was collected from tissues and cells by Trizol reagent (Thermo Fisher Scientific, USA) according to the standard protocol. Subsequently, 1.5 μg of RNA was utilized for cDNA synthesis employing the First Strand cDNA Synthesis Kit (Takara, Japan). For quantitative analysis of gene expression, the synthesized cDNA was utilized. SYBR Green Mix (Thermo Fisher Scientific, USA) was employed to perform the real-time polymerase chain reaction (PCR), and the expressions of the target genes were determined by $2^{-\Delta\Delta\text{Ct}}$ method with GAPDH as the internal control.

Western blot (WB)

The WB was performed in accordance with standard procedures[17]. Cells underwent lysis in RIPA buffer (Beyotime, China), and denatured samples (30 μg) were loaded onto 10% acrylamide gels. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride membranes and blocked with 5% skim milk for 2 hours. The membranes were treated with the anti-YTHDF3 (Abcam, #ab220161), anti-FSP1 (Abcam, #1978968), anti-GPX4 (Abcam, #ab125066), and anti- β -ACTIN (Cell Signaling Technology, #2128) for an overnight period at 4°C . Membranes were probed with HRP-conjugated secondary antibodies (anti-rabbit, Cell Signaling Technology, #7074) for 1 hour indoor following primary antibody incubation. PierceTM ECL Western Blotting Substrate from Thermo Fisher Scientific (USA) was used to identify signals.

Cell Count Kit-8 (CCK-8)

Cell viability was evaluated by the CCK-8 assay (Beyotime, China)[18]. The cells were initially seeded at a density of 1×10^5 cells per well in 96-well plates. On the second day, after 6-hour transfection, the culture medium supplemented with 10 $\mu\text{M/L}$ RSL3 was introduced, and subsequent cell incubation occurred for 24, 48, 72, and 96 hours. Following this, CCK-8 (10 μL) was added to each well, and the cell plates were incubated at 37°C for 1 hour. Absorbance was measured at 450 nm using a microplate reader (Model 680 Microplate Reader; Bio-Rad, USA).

Apoptosis

Apoptosis in cells was assessed using the V-FITC Membrane Protein Apoptosis Assay Kit (CA1020, Solarbio, Beijing, China)[19]. 1 ml of cell suspension (1×10^6 cells/mL) underwent centrifugation at 1000g for 5 minutes at 4°C. After discarding the supernatant, 1 mL precooled PBS buffer was added. The mixture underwent subsequent centrifugation, and the supernatant was discarded, with these steps repeated twice. Following this, cells were resuspended in 100 μL binding buffer, stained with 5 μL Annexin V-FITC in the dark for 15 min, and then 5 μL propidium iodide (PI) in the dark for 5 min. The cell suspension was then analyzed using the NovoCyte flow cytometer (Agilent Technologies) to quantify apoptotic cells based on fluorescence emissions.

Enzyme-linked immunosorbent assay (ELISA)

The CoQ10 levels were measured utilizing the CoQ10 ELISA Kit (CUSABIO, CSB-E14081h)[20]. Following the specified treatments, PBS was used to homogenize the collected cells, which were then centrifuged at 10000 g for 10 minutes. The supernatant was loaded onto the assay plate and thoroughly mixed with the HRP-conjugated reagent. After that, the mixture was incubated for 37 minutes at 40°C. After five washes with wash buffer, TMB substrate was added to each well, and the plate was incubated at 20°C in darkness for 37 minutes. Finally, stop solution was added, and the plate was read at 450nm to measure the absorbance.

MDA and NADPH measurement

MDA (malondialdehyde) levels were quantified using the TBA assay kit (A003-1-2, Nanjing Jiancheng Bioengineering Institute) following the manufacturer's instructions[21]. Intracellular NADPH levels were determined using the Coenzyme II (NADP/NADPH) content test kit (A115-1-1, Nanjing Jiancheng Bioengineering Institute) in accordance with the manufacturer's instructions[22].

Reactive oxygen species (ROS) detection and analysis

ROS levels were detected by ROS detection kit with 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (DCFHDA) from Thermo Fisher Scientific[23]. Cells were treated and then exposed to DCFHDA, which becomes fluorescent upon oxidation by ROS. Fluorescence intensity, indicating ROS levels, was

monitored and quantified using a flow cytometer as per the manufacturer's instructions.

Iron determination

Cellular iron concentrations relative to Fe^{2+} and Fe^{3+} were evaluated using the Iron Detection Assay Kit (ab83366, Abcam)[24]. Cells were homogenized in a 4-10 volume of iron determination buffer. To remove insoluble particles, the homogenate was centrifuged at 16000g for 10 minutes. The resultant supernatant was transferred to a 96-well plate and then diluted with assay buffer to a final volume of 100 μL . 100 μL of iron probe was added after the reaction mixture had been incubated at 37°C for 30 minutes. The reaction mixture was then incubated at 37°C for an additional 60 minutes. Following incubation, the absorbance was measured at 593 nm using a microplate reader.

Transmission electron microscope

Cells were fixed in 2.5% glutaraldehyde solution with Millonig's phosphate buffer (pH = 7.3). After three washes with Millonig's phosphate buffer, cells were incubated in 1% osmium tetroxide for 1 hour, followed by three washes with Millonig's phosphate buffer. Samples were dehydrated in increasing concentrations of acetone, embedded in a 1:1 mixture of acetone and resin for 12 hours, polymerized overnight at 37 °C in 100% resin, and further polymerized for 12 hours at 60 °C. Ultra-thin sections were cut using a Leica Ultracut microtome (Leica EM UC7), stained with uranyl acetate and lead nitrate, and examined in Hitachi HT-7700 electron microscope[20].

Mitochondrial membrane potential (MMP) assessment

MMP was evaluated by JC-1 Mitochondrial Membrane Potential Detection Kit (M8650, Solarbio, Beijing, China)[25]. Cells were washed before being exposed to the JC-1 working solution for 37 minutes at 30°C in a CO₂ incubator. Live cells were photographed using a confocal laser scanning microscope after incubation. Meanwhile, cells treated with CCCP as per instructions served as the negative control for MMP assessment. In the presence of a high MMP, JC-1 aggregates glow red whereas JC-1 monomers fluoresce green. Using ImageJ software created by Wayne Rasband, MD, USA, the fast exposure confocal images were measured for the average fluorescence intensity of particular locations.

m6A RNA methylation quantification

The m6A RNA methylation levels were measured by EpiQuik m6A RNA Methylation Quantitative Assay Kit (Colorimetric Method, Biyuntian Biotechnology, China) following instructions[26]. For each assay well, 6 ng RNA and the appropriate antibody were added. 200 nm absorbance values were measured and computed as directed by the manufacturer's protocol.

mRNA stability analysis

To investigate mRNA stability, the Actinomycin D (Act D) chase method was employed,

as described previously[27].

Tumor xenografting

Vital River Laboratory (China) provided six-week-old BALB/c nude mice, which were raised under the recommended, pathogen-free conditions. The left flank fat pad of the nude mice was injected with 1×10^6 U2OS cells stably transfected with siYTHDF3 or shNC (n = 6 per group). After a 30-day growth period, the mice were euthanized, and the tumors were prepared for immunostaining and H&E staining[28].

Tissue processing and histological analysis

Tissues were fixed in 4% paraformaldehyde, dehydrated, and subsequently embedded in paraffin blocks. Sections were cut from the blocks and utilized for both Hematoxylin and Eosin (HE) staining [29] and Immunohistochemistry (IHC)[30]. The sections in IHC were kept with primary antibodies, including anti-YTHDF3 (Abcam, ab220161), anti-FSP1 (Abcam, ab197896), and anti-GPX4 (Abcam, ab125066). These primary antibodies were selected to target specific proteins of interest in the study. All images were acquired using an Olympus microscope (Olympus, Japan).

Statistical analysis

One-way ANOVA with Tukey's test or the t-test was used to assess the experimental data (n=3, $P < 0.05$). Representative images were chosen from multiple sections. IHC staining intensity was statistically evaluated using Mann-Whitney U test. Results are presented as mean \pm SD/SEM.

Result

Clinical assessment reveals m6A modification and ferroptosis-related proteins in OS

To investigate the mechanisms of m6A modification in clinical contexts, we explored 10 OS patient specimens alongside 10 adjacent non-tumor samples. As illustrated in Figure 1, upregulated YTHDF3 in OS patients was unveiled. Moreover, ferroptosis-associated proteins, including glutathione peroxidase 4 (GPX4) and FSP1, were markedly elevated in OS patients. Overall, these findings suggest the involvement of m6A modification and ferroptosis in OS, providing insights into potential underlying mechanisms.

RSL3-mediated ferroptosis induction and YTHDF3 regulation in OS cells

RSL3, a classical small molecule known to induce ferroptosis by inhibiting GPX4's peroxidase activity, was investigated for appropriate intervention conditions[31]. Concentration gradient and time-point experiments were conducted by subjecting cells to gradient concentrations of RSL3 for 24-48-72 hours. The IC₅₀ of RSL3 in U2OS was approximately 11.90-5.823-4.038 μ M (Figure 2A), while in Mg-63 cells, it was about 22.59-9.445-7.104 μ M (Figure 2B). Further experiments employed 5 μ M RSL3 treatment for 48 hours in U2OS cells and 10 μ M RSL3 for 48 hours in Mg-63 cells to establish ferroptosis models. Transmission electron microscopy revealed characteristic

ultrastructural changes associated with ferroptosis post-RSL3 treatment, including mitochondrial shrinkage and pronounced chromatin decondensation in the nucleus (Figure 2C). Consistent with expectations, qRT-PCR and WB analysis demonstrated significant suppression of YTHDF3, GPX4, and FSP1 mRNA and protein levels upon RSL3 treatment (Figure 2D-H).

Modulation of YTHDF3 alters ferroptosis susceptibility in OS cells

Lentivirus-mediated vectors targeting YTHDF3 (shYTHDF3) and carrying YTHDF3 gene (OE-YTHDF3) were introduced into U2OS and Mg-63 OS cell lines. qRT-PCR confirmed knockdown and overexpression efficiency (Figure 3A-B). CCK-8 assays revealed increased proliferation in OE-YTHDF3 cells compared to OE-NC, while shYTHDF3 cells exhibited decreased proliferation compared to Sh-NC (Figure 3C). Flow cytometry-based apoptosis detection demonstrated reduced apoptosis rates in OE-YTHDF3 cells and elevated rates in shYTHDF3 cells (Figure 3D). ELISA results displayed reduced malondialdehyde (MDA) levels in YTHDF3-overexpressing cells, suggesting lower lipid oxidation and enhanced oxidative damage (Figure 3E). Conversely, shYTHDF3 cells exhibited elevated MDA levels (Figure 3E). Flow cytometry analysis revealed that YTHDF3 overexpression significantly lowered ROS levels, while shYTHDF3 significantly increased ROS levels (Figure 3F). JC-1 staining indicated that YTHDF3 overexpression elevated mitochondrial membrane potential, while YTHDF3 knockdown reduced it (Figure 3G). Moreover, the overexpression of YTHDF3 led to a notable reduction in intracellular levels of both Fe²⁺ and Fe³⁺, while conversely, the knockdown of YTHDF3 resulted in opposite results (Figure 3H-I).

YTHDF3 modulation affects FSP1, GPX4, CoQ10, and NADPH levels in OS cells

YTHDF3 overexpression remarkably increased the mRNA and protein expressions of FSP1 and GPX4 in OS cells, while YTHDF3 knockdown notably suppressed them (Figure 4A-4D). Transmission electron microscopy exhibited that YTHDF3 overexpression attenuated RSL3-induced alterations, including mitochondrial shrinkage, chromatin decondensation, and nuclear changes (Figure 4E). Conversely, YTHDF3 knockdown exacerbated RSL3-induced ferroptosis morphological features (Figure 4F). ELISA results demonstrated elevated CoQ10 levels upon YTHDF overexpression (Figure 4F), whereas shYTHDF cells showed reduced CoQ10 levels (Figure 4G). YTHDF3 overexpression increased NADPH levels in OS cells, while YTHDF3 knockdown yielded the opposite effect (Figure 4H). These findings illuminate the intricate role of YTHDF3 in regulating FSP1, GPX4, CoQ10, and NADPH levels, contributing to the modulation of ferroptosis susceptibility in OS cells.

Impact of FSP1 modulation on ferroptosis susceptibility in OS cells

Lentivirus-mediated vectors targeting FSP1 (shFSP1) and carrying FSP1 gene (OE-FSP1) were introduced into U2OS and Mg-63 OS cell lines, followed by qRT-PCR to validate knockdown and overexpression efficiency (Figure 5A-B). CCK-8 assays demonstrated enhanced proliferation in OE-FSP1 cells compared to OE-NC, while

shFSP1 cells exhibited increased proliferation compared to Sh-NC (Figure 5C). Cell apoptosis analysis revealed reduced apoptosis rates in OE-FSP1 cells and elevated rates in shFSP1 cells (Figure 5D). ELISA results indicated reduced MDA levels upon FSP1 overexpression (Figure 5E), whereas shFSP1 cells showed higher MDA levels (Figure 5E). Flow cytometry analysis demonstrated significantly lowered ROS levels in FSP1-overexpressing cells, while shFSP1 significantly increased ROS levels (Figure 5F). JC-1 staining revealed that FSP1 overexpression elevated mitochondrial membrane potential, while FSP1 knockdown reduced it (Figure 5G). Moreover, FSP1 overexpression reduced cellular Fe^{2+} and Fe^{3+} levels, whereas FSP1 knockdown yielded opposite results (Figure 5H-I).

FSP1 modulation influences GPX4 levels and ferroptosis susceptibility in OS cells

It was found significant upregulation of GPX4 mRNA and protein levels upon FSP1 overexpression in OS cells, while FSP1 knockdown led to pronounced suppression of GPX4 levels without affecting YTHDF3 expression (Figure 6A-6D). Transmission electron microscopy demonstrated that FSP1 overexpression mitigated RSL3-induced alterations including mitochondrial shrinkage, chromatin decondensation, and nuclear changes (Figure 6E). Conversely, FSP1 knockdown exacerbated RSL3-induced ferroptosis morphological features (Figure 6F). ELISA results indicated increased CoQ10 levels upon FSP1 overexpression, whereas shFSP1 cells exhibited lower CoQ10 levels (Figure 6G). FSP1 overexpression also elevated NADPH levels in OS cells, while FSP1 knockdown yielded the opposite effect (Figure 6H).

YTHDF3-mediated m6A modification of FSP1 modulates ferroptosis in OS

Given YTHDF3's role in regulating ferroptosis in OS cells, our study aimed to explore the potential mechanisms underlying YTHDF3-mediated ferroptosis regulation. Functional experiments revealed the involvement of FSP1 in modulating ferroptosis in OS. As depicted in Figure 7A-B, RSL3-induced treatment significantly reduced the m6A methylation level of FSP1 in OS cells. To investigate YTHDF3's regulatory impact on FSP1 mRNA, RNA decay analyses were conducted in OS cells. The results demonstrated that YTHDF3 overexpression markedly elevated FSP1 mRNA levels following Act D treatment (Figure 7C), while YTHDF3 silencing inhibited FSP1 mRNA levels upon Act D treatment (Figure 7D).

YTHDF3 mediates FSP1-regulated ferroptosis in OS cells

In order to confirm FSP1 as the mediator of YTHDF3-regulated cell ferroptosis, rescue experiments were conducted. The knockdown of YTHDF3 significantly inhibited GPX4 and FSP1 levels in U2OS and Mg-63 cells, while overexpression of FSP1 restored the levels of GPX4 and FSP1, without affecting YTHDF3 (Figure 8A-D). As shown in Figure 8E, sh-YTHDF3 inhibited the proliferation and induced apoptosis of U2OS and Mg-63 cells, whereas overexpression of FSP1 reversed these effects, restoring cell proliferation and inhibiting apoptosis (Figure 8E-8F). Over-expressed FSP1 attenuated the accumulation of MDA, ROS, Fe^{2+} , and Fe^{3+} induced by sh-YTHDF3 (Figure 8G,

8H, 8J, and 8K). Moreover, FSP1 overexpression restored the decreased mitochondrial membrane potential caused by sh-YTHDF3 (Figure 8I). Transmission electron microscopy revealed that YTHDF3 knockdown aggravated the ferroptosis features induced by RSL3, including mitochondrial shrinkage and chromatin decondensation, while FSP1 overexpression alleviated these morphological changes (Figure 8L). Furthermore, sh-YTHDF3 significantly inhibited CoQ10 and NADPH levels in OS cells, while FSP1 overexpression restored these levels (Figure 8M-N). These results collectively emphasize the role of FSP1 as a pivotal downstream effector of YTHDF3 in regulating ferroptosis in OS cells.

Implications of YTHDF3 in regulating FSP1-CoQ10-GAPDH Axis and ferroptosis

In the *in vivo* investigation, we subcutaneously implanted sh-YTHDF3 U2OS cells into mice. Histopathological analysis showed that the tumor pathology changes in the YTHDF3 knockdown group showed sparsely arranged and impaired texture compared with the control group, which improved the tumor pathology of the xenografts (Figure 9A). IHC results showed that the percentage of YTHDF3, GPX4, and FSP1-positive cells in the sh-YTHDF3 group was lower than about half of that in the sh-NC group (Figure 9B-E). qRT-PCR and WB analysis further confirmed that YTHDF3 knockdown significantly inhibited FSP1 and GPX4 levels (Figure 9F-9I). Notably, YTHDF3 knockdown led to the elevation of MDA, ROS, Fe²⁺, and Fe³⁺ levels in the tumor microenvironment (Figure 9J-M). Additionally, sh-YTHDF3 markedly suppressed CoQ10 and NADPH levels in OS tumors (Figure 9N-O).

Discussion

In recent years, m6A modification has emerged as a pivotal post-transcriptional regulatory mechanism, exerting far-reaching effects on various cellular processes, including gene expression, RNA stability, and protein translation[32-34]. Growing evidence underscores the intricate connection between dysregulated m6A modifications and tumorigenesis[35, 36]. YTHDF3, a key reader protein recognizing m6A-modified mRNAs, has attracted considerable attention due to its prominent role in cancer biology[37, 38]. Research has revealed that YTHDF3 induces translation of m6A-enriched transcripts, thereby facilitating brain metastasis in breast cancer[39]. In ocular melanoma, YTHDF3 enhances CTNNB1 translation, intensifying the oncogenicity of cancer stem-like cells[40].

Herein, we initially measured YTHDF3 mRNA expression in OS and normal tissues. It was found that YTHDF3 levels were remarkably high in tumor tissues, supporting earlier observations. To delineate the functional role of YTHDF3 in OS progression, an array of *in vitro* and *in vivo* assays were conducted. YTHDF3 significantly promoted cell proliferation while suppressing apoptosis in OS cells. MDA, an end-product of lipid peroxidation, emerges as both a biomarker and contributor to ferroptosis cascades, amplifying oxidative stress and ultimately driving cellular demise[41, 42]. Meanwhile, ROS, with their dual role as signaling molecules and oxidative agents, intricately

participate in propagating lipid peroxidation and disrupting redox equilibrium, thereby orchestrating ferroptosis[43]. Disturbances in mitochondrial membrane potential potentiate iron-induced cytotoxicity by disrupting energy homeostasis and redox signaling, playing a pivotal role in the early events of ferroptosis[44]. Elevated iron levels fuel the Fenton reaction, fostering ROS generation and lipid peroxidation, thereby exacerbating the ferroptosis response[45]. In our study, we reveal that YTHDF3 is capable of suppressing levels of MDA, ROS, and iron ions in OS cells, raising mitochondrial membrane potential, inhibiting ferroptosis, and thereby promoting OS progression.

In the realm of ferroptosis, the roles of FSP1 and GPX4 have garnered substantial attention for their pivotal involvement in orchestrating cellular demise pathways. FSP1, a recently identified protein, has emerged as a critical sentinel in counteracting ferroptosis cell death[46, 47]. It functions as an indispensable constituent of the CoQ10 (coenzyme Q10) biosynthesis pathway, thereby facilitating the reduction of lipid peroxides and preserving the integrity of cellular membranes[48, 49]. Conversely, GPX4, a selenoenzyme, occupies a central position in defense against ferroptosis insults, intercepting the perilous cascade of lipid peroxidation[50]. In concert, the concerted activities of FSP1 and GPX4 finely tune a defensive mechanism to thwart ferroptosis[51]. Notably, levels of FSP1 and GPX4 are significantly elevated in OS tissues. Cell assays verified knockdown of YTHDF3 substantially down-regulated GPX4 and FSP1 levels. Furthermore, induction by RSL3 significantly diminished the m6A methylation of FSP1 in OS cells. Overexpression of FSP1 in OS cells was found to bolster cell proliferation, inhibit apoptosis, and concurrently restrain iron-mediated cell death. Collectively, these data corroborate the potential downstream targeting of FSP1 by YTHDF3 in OS.

In recent years, the role of Ferroptosis Suppressor Protein (FSP) in cancer research has garnered substantial attention, emerging as a critical player in cancer progression and malignancy[51, 52]. FSP1 has been implicated in various aspects of tumor development, including metastasis, epithelial-mesenchymal transition (EMT), and tumor-stroma interactions[53, 54]. Notably, its involvement in cancer-related processes is linked to its regulatory role in N6-methyladenosine (m6A) RNA modification, a pivotal post-transcriptional mechanism influencing gene expression[55, 56]. For instance, a pioneering study by Song et al. revealed that exosomal miR-4443, regulated by METTL3 via m6A modification, mediates ferroptosis by modulating FSP1 expression, thereby promoting cisplatin resistance in NSCLC[8]. Similarly, another study by Bu et al. stabilized FSP1 mRNA through m6A modification, thereby inhibiting ferroptosis and driving glioma progression[57]. These findings accentuate the importance of FSP1 as an m6A-modified gene in diverse cancer types. In this study, stability analyses demonstrated that inhibiting YTHDF3 significantly compromised the stability of FSP1 mRNA in OS cells, further confirming YTHDF3's ability to enhance the stability of FSP1 mRNA. Functional rescue experiments validated the impact of the YTHDF3/FSP1

axis on OS. Knockdown of YTHDF3 induced decreased proliferation and ferroptosis, both of which could be rescued by FSP1 overexpression. Furthermore, FSP1 overexpression partially restored the downregulation of CoQ10 and NADPH caused by YTHDF3 knockdown. Collectively, these results suggest that YTHDF3 may promote FSP1 mRNA translation in an m6A-dependent manner, thereby inhibiting ferroptosis through the FSP1-CoQ10-NADPH pathway and promoting OS progression.

Conclusion

Collectively, we embarked on an investigation into the pivotal roles played by YTHDF3 and FSP1 in the regulation of the CoQ10-GAPDH axis and ferroptosis in OS. Initially, we established a ferroptosis model in U2OS and Mg-63 cells through treatment with RSL3. Our findings revealed that the overexpression of YTHDF3 exerted a mitigating effect on ferroptosis, whereas its knockdown intensified this cellular process. Notably, FSP1 emerged as a key mediator of YTHDF3's regulatory impact. Mechanistically, YTHDF3 enhanced the stability and translation of m6a-modified FSP1 mRNA and altered CoQ10 and GAPDH levels to regulate ferroptosis. This study not only enhances our understanding of ferroptosis regulation but also sheds light on the significance of YTHDF3 and FSP1 as potential targets for therapeutic intervention in OS, offering new prospects for cancer treatment strategies.

List of abbreviations

Osteosarcoma (OS)
Apoptosis-Inducing Factor Mitochondria-Associated 2 (AIFM2)
Ferroptosis Suppressor Protein 1 (FSP1)
Programmed Cell Death Protein 3 (PRG3)
Non-small cell lung cancer (NSCLC)
N6-methyladenosine (m6A)
YTH domain family protein 3 (YTHDF3)
Dulbecco's Modified Eagle Medium (DMEM)
Dimethyl sulfoxide (DMSO)
Real-time polymerase chain reaction (PCR)
Western blot (WB)
Cell Count Kit-8 (CCK-8)
Propidium iodide (PI)
Enzyme-linked immunosorbent assay (ELISA)
MDA (malondialdehyde)
Reactive oxygen species (ROS)
Dichlorodihydrofluorescein diacetate (DCFHDA)
Mitochondrial membrane potential (MMP)
Actinomycin D (Act D)
Hematoxylin and Eosin (HE)
Immunohistochemistry (IHC)

Glutathione peroxidase 4 (GPX4)
Malondialdehyde (MDA)
CoQ10 (coenzyme Q10)
Ferroptosis Suppressor Protein (FSP)
Epithelial-mesenchymal transition (EMT)

Declarations

Ethics approval and consent to participate

Ethics Committee of The Second Hospital Affiliated with Anhui Medical University approved the study in accordance with ethical standards (No. SL-YX[YS]2023-019).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the Research Fund of Anhui Institute of Translational Medicine [No. 2023zhyx-C74] and the University Natural Science Foundation of Anhui Province [No. 2023AH053173].

Authors' contributions

LW, LQN and ZN designed the study. LW, LQN, ZS and ZJF collected the patient data. LW, ZN, ZS, ZJF and JJH analyzed and interpreted the patient data. LQN, ZN, ZJF and JJH wrote the manuscript. LW, LQN, ZN, ZS were responsible for the revision. ZJF and JJH were responsible for communication. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to personal privacy but are available from the corresponding author on reasonable request.

Reference

1. Nørregaard, K.S., et al., *Osteosarcoma and metastasis associated bone degradation—A tale of osteoclast and malignant cell cooperativity*. International Journal of Molecular Sciences, 2021. **22**(13): p. 6865.
2. Zhao, Z., et al., *Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells*. Cancer Cell International, 2019. **19**(1): p. 1-15.
3. Kudarha, R., N. Dhas, and S. Mutalik, *Distinct features of iron based metal organic frameworks (MOFs) for ferroptosis mediated cancer therapy: A comprehensive review*. Coordination Chemistry Reviews, 2023. **494**: p. 215330.
4. Lin, K.-J., et al., *Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease*. Cells, 2022. **11**(23): p. 3829.
5. Lee, J. and J.-L. Roh, *Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance*. Antioxidants, 2023. **12**(6): p. 1218.
6. Guo, J., L. Chen, and M. Ma, *Ginsenoside Rg1 Suppresses Ferroptosis of Renal Tubular Epithelial Cells in Sepsis-induced Acute Kidney Injury via the FSP1-CoQ10-NAD (P) H Pathway*. Current Medicinal Chemistry, 2023.
7. Li, W., et al., *FSP1: a key regulator of ferroptosis*. Trends in Molecular Medicine, 2023.
8. Song, Z., et al., *Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis*. Life sciences, 2021. **276**: p. 119399.
9. Sun, Y., et al., *N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential*. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2023: p. 194967.
10. Chen, D., et al., *N6-methyladenosine RNA-binding protein YTHDF1 in gastrointestinal cancers: Function, molecular mechanism and clinical implication*. Cancers, 2022. **14**(14): p. 3489.
11. Chang, L.-L., et al., *Emerging role of m6A methylation modification in ovarian cancer*. Cancer Cell International, 2021. **21**: p. 1-16.
12. Yang, Z., et al., *ALKBH5 Regulates Stat3 Activity to Affect the Proliferation and Tumorigenicity of Osteosarcoma via an m6A-YTHDF2-Dependent Manner*. SSRN Electronic Journal, 2020.
13. Li, H.-B., et al., *METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma*. EBioMedicine, 2022. **82**.
14. Xu, Y., et al., *YTH domain proteins: a family of m6A readers in cancer progression*. Frontiers in oncology, 2021. **11**: p. 629560.
15. Yu, Y., et al., *m6A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer*. Cellular Signalling, 2023. **108**: p. 110699.

16. Ni, W., et al., *Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3*. *Molecular cancer*, 2019. **18**(1): p. 1-20.
17. Pillai-Kastoori, L., A.R. Schutz-Geschwender, and J.A. Harford, *A systematic approach to quantitative Western blot analysis*. *Analytical biochemistry*, 2020. **593**: p. 113608.
18. Li, S., et al., *RSL3 drives ferroptosis through NF- κ B pathway activation and GPX4 depletion in glioblastoma*. *Oxidative Medicine and Cellular Longevity*, 2021. **2021**.
19. Wang, D.P., et al., *microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-dependent Notch signaling pathway*. *Journal of Cellular Physiology*, 2020. **235**(3): p. 2492-2505.
20. Zeng, F., et al., *Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis*. *Redox Biology*, 2023. **61**: p. 102653.
21. Chen, Y., et al., *Pterostilbene as a protective antioxidant attenuates diquat-induced liver injury and oxidative stress in 21-day-old broiler chickens*. *Poultry science*, 2020. **99**(6): p. 3158-3167.
22. Ma, Y., et al., *Loss of heterozygosity for KrasG12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma*. *Biochemical and Biophysical Research Communications*, 2020. **526**(4): p. 880-888.
23. Chai, Y., et al., *Dexmedetomidine attenuates LPS-induced monocyte-endothelial adherence via inhibiting Cx43/PKC- α /NOX2/ROS signaling pathway in monocytes*. *Oxidative Medicine and Cellular Longevity*, 2020. **2020**.
24. Nikaido, Y., et al., *The role of neutrophil gelatinase-associated lipocalin and iron homeostasis in object recognition impairment in aged sepsis-survivor rats*. *Scientific Reports*, 2022. **12**(1): p. 249.
25. Deng, X., et al., *Allicin attenuates myocardial apoptosis, inflammation and mitochondrial injury during hypoxia-reoxygenation: an in vitro study*. *BMC Cardiovascular Disorders*, 2021. **21**(1): p. 1-9.
26. Bornaque, F., et al., *Glucose regulates m6A methylation of RNA in pancreatic Islets*. *Cells*, 2022. **11**(2): p. 291.
27. Xia, P., et al., *MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma*. *Cell death & disease*, 2021. **12**(7): p. 691.
28. Park, K.-R., H.-M. Yun, and J.T. Hong, *G721-0282 inhibits cell growth and induces apoptosis in human osteosarcoma through down-regulation of the STAT3 pathway*. *International Journal of Biological Sciences*, 2020. **16**(2): p. 330.

29. Chlipala, E., et al., *Optical density-based image analysis method for the evaluation of hematoxylin and eosin staining precision*. Journal of histotechnology, 2020. **43**(1): p. 29-37.
30. Lin, F., et al., *Handbook of practical immunohistochemistry: frequently asked questions*. 2022: Springer Nature.
31. Sekhar, K.R., et al., *Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer*. Scientific Reports, 2022. **12**(1): p. 19396.
32. Song, T., et al., *Novel insights into adipogenesis from the perspective of transcriptional and RNA N6-methyladenosine-mediated post-transcriptional regulation*. Advanced science, 2020. **7**(21): p. 2001563.
33. Fu, Y., et al., *Gene expression regulation mediated through reversible m6A RNA methylation*. Nature Reviews Genetics, 2014. **15**(5): p. 293-306.
34. Meyer, K.D., *m6A-mediated translation regulation*. Biochimica et Biophysica Acta (Bba)-Gene Regulatory Mechanisms, 2019. **1862**(3): p. 301-309.
35. Panneerdoss, S., et al., *Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression*. Science advances, 2018. **4**(10): p. eaar8263.
36. He, P.C. and C. He, *m6A RNA methylation: from mechanisms to therapeutic potential*. The EMBO journal, 2021. **40**(3): p. e105977.
37. Zaccara, S. and S.R. Jaffrey, *A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA*. Cell, 2020. **181**(7): p. 1582-1595. e18.
38. Liu, T., et al., *The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation*. Nucleic acids research, 2020. **48**(7): p. 3816-3831.
39. Chang, G., et al., *YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis*. Cancer cell, 2020. **38**(6): p. 857-871. e7.
40. Ran, Y., et al., *N6-methyladenosine functions and its role in skin cancer*. Experimental Dermatology, 2023. **32**(1): p. 4-12.
41. Chen, X., et al., *Organelle-specific regulation of ferroptosis*. Cell Death & Differentiation, 2021. **28**(10): p. 2843-2856.
42. Chen, X., et al., *Ferroptosis in infection, inflammation, and immunity*. Journal of Experimental Medicine, 2021. **218**(6): p. e20210518.
43. Zeng, W., et al., *The interplay of oncogenic signaling, oxidative stress and ferroptosis in cancer*. International Journal of Cancer, 2023.
44. Sun, K., et al., *The mitochondrial regulation in ferroptosis signaling pathway and its potential strategies for cancer*. Biomedicine & Pharmacotherapy, 2023. **169**: p. 115892.
45. Battaglia, A.M., et al., *Ferroptosis and cancer: mitochondria meet the "iron maiden" cell death*. Cells, 2020. **9**(6): p. 1505.
46. Bersuker, K., et al., *The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis*. Nature, 2019. **575**(7784): p. 688-692.

47. Brown, C.W., et al., *Prominin2 drives ferroptosis resistance by stimulating iron export*. *Developmental cell*, 2019. **51**(5): p. 575-586. e4.
48. Zhao, Y., et al., *The role of Ferroptosis in blood–brain barrier injury*. *Cellular and Molecular Neurobiology*, 2023. **43**(1): p. 223-236.
49. Luo, M., et al., *Targeting lipid metabolism for ferroptotic cancer therapy*. *Apoptosis*, 2023. **28**(1-2): p. 81-107.
50. Su, L.-J., et al., *Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis*. *Oxidative medicine and cellular longevity*, 2019. **2019**.
51. Doll, S., et al., *FSP1 is a glutathione-independent ferroptosis suppressor*. *Nature*, 2019. **575**(7784): p. 693-698.
52. Yang, J., et al., *Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance*. *Advanced Healthcare Materials*, 2022. **11**(13): p. 2102799.
53. Bornes, L., et al., *Fsp1-mediated lineage tracing fails to detect the majority of disseminating cells undergoing EMT*. *Cell Reports*, 2019. **29**(9): p. 2565-2569. e3.
54. Ni, Y., et al., *The role of tumor-stroma interactions in drug resistance within tumor microenvironment*. *Frontiers in Cell and Developmental Biology*, 2021. **9**: p. 637675.
55. Zhang, Z., et al., *N6-methyladenosine-sculpted regulatory landscape of noncoding RNA*. *Frontiers in Oncology*, 2021. **11**: p. 743990.
56. Feng, H., et al., *Effects of writers, erasers and readers within miRNA-related m6A modification in cancers*. *Cell Proliferation*, 2023. **56**(1): p. e13340.
57. Bu, C., et al., *Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability*. *Clinical and Translational Oncology*, 2023. **25**(5): p. 1378-1388.

Figure Legends

Figure 1 Clinical evaluation reveals m6A modification and ferroptosis-related protein expression in OS.

Quantitative real-time polymerase chain reaction (qRT-PCR) analysis depicting the expression levels of YTHDF3 (A), FSP1 (B) and GPX4 (C) in 10 OS patient specimens compared to 10 adjacent non-tumor samples. Western blot analyses displaying protein expression levels of YTHDF3, GPX4, and FSP1 in 10 OS patient specimens along with 10 adjacent non-tumor samples (D).

** $P < 0.01$, *** $P < 0.001$

Figure 2 Investigation of RSL3-mediated ferroptosis induction and YTHDF3 regulation in OS cells.

(A) Concentration-response experiment depicting the IC₅₀ values of RSL3 in U2OS cells, measured at approximately 11.90-5.823-4.038 μM . (B) Concentration-response experiment revealing the IC₅₀ values of RSL3 in Mg-63 cells, recorded at approximately 22.59-9.445-7.104 μM . (C) Transmission electron microscopy images showcasing characteristic ultrastructural changes associated with ferroptosis following RSL3 treatment. (D) qRT-PCR analysis revealing the modulation of YTHDF3 mRNA expression levels (E), GPX4 (F), and FSP1 (G) in response to RSL3 treatment. (H) Western blot analysis displaying the alterations in YTHDF3, GPX4, and FSP1 protein expression levels in response to RSL3 treatment.

**** $P < 0.0001$

Figure 3 Impact of YTHDF3 modulation on ferroptosis susceptibility in OS cells.

(A-B) qRT-PCR validation confirming the efficiency of knockdown and overexpression strategies for the respective targets. (C) Cell Counting Kit-8 (CCK-8) assays depict the proliferative capacity of OE-YTHDF3 cells relative to OE-NC, and proliferation in shYTHDF3 cells compared to Sh-NC controls. (D) Flow cytometry-based apoptosis analysis reveals the apoptotic rates in OE-YTHDF3 cells and shYTHDF3 cell. (E) Enzyme-linked immunosorbent assay (ELISA) results demonstrate alterations in malondialdehyde (MDA) levels in YTHDF3-overexpressing and YTHDF3-knockdown. (F) Flow cytometry analysis illustrates the impact of YTHDF3 overexpression and knockdown on intracellular reactive oxygen species (ROS) levels. (G) JC-1 staining provides visual representation of mitochondrial membrane potential changes in response to YTHDF3 overexpression and knockdown. (H-I) Alterations in cellular Fe^{2+} and Fe^{3+} levels upon YTHDF3 overexpression and knockdown through iron assay kit.

** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Figure 4 Influence of YTHDF3 modulation on FSP1, GPX4, CoQ10, and NADPH levels in OS cells.

(A-D) qRT-PCR and Western blot confirm YTHDF3's regulation of FSP1 and GPX4 in OS cells. (E) Transmission electron microscopy images reveal YTHDF3 overexpression's counteraction of RSL3-induced ferroptosis-associated morphological

changes. (F) Transmission electron microscopy images depict YTHDF3 knockdown's attenuation of RSL3-induced ferroptosis-associated morphological alterations. CoQ10 (G) and NADPH (H) level were determined upon YTHDF3 overexpression and knockdown.

** $P < 0.01$, **** $P < 0.0001$

Figure 5 Influence of FSP1 Modulation on Ferroptosis Susceptibility in OS Cells.

(A-B) Lentivirus introduced FSP1 targeting (shFSP1) and carrying FSP1 gene (OE-FSP1) constructs in U2OS and Mg-63 cells, confirmed by qRT-PCR for knockdown and overexpression efficiency. (C) CCK-8 assays show proliferation differences between OE-FSP1 and OE-NC, as well as shFSP1 and Sh-NC cells. (D) Flow cytometry-based apoptosis analysis reveals varying rates in OE-FSP1 and shFSP1 cells. (E) ELISA indicates MDA level changes upon FSP1 overexpression and knockdown. (F) Flow cytometry analysis demonstrates ROS level alterations with FSP1 manipulation. (G) JC-1 staining reflects mitochondrial membrane potential changes caused by FSP1 modulation. (H-I) FSP1's impact on cellular Fe^{2+} and Fe^{3+} levels is observed through iron assay kit.

** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Figure 6 Impact of FSP1 Modulation on GPX4 Levels and Ferroptosis Susceptibility in OS Cells.

(A-B) qRT-PCR and Western blot confirm FSP1's regulation of YTHDF3 and GPX4 in OS cells. (E) Transmission electron microscopy images reveal FSP1 overexpression's counteraction of RSL3-induced ferroptosis-associated morphological changes. (F) Transmission electron microscopy images depict FSP1 knockdown's attenuation of RSL3-induced ferroptosis-associated morphological alterations. CoQ10 (G) and NADPH (H) level were determined upon FSP1 overexpression and knockdown.

**** $P < 0.0001$

Figure 7 YTHDF3-Mediated m6A Modification of FSP1 Modulates Ferroptosis in OS.

(A-B) RSL3-induced treatment alters FSP1 m6A methylation in OS cells, measured by EpiQuik m6A RNA Methylation Quantitative Assay Kit. (C) YTHDF3 overexpression affects FSP1 mRNA levels following Act D treatment, observed through RNA decay analyses. (D) YTHDF3 silencing influences FSP1 mRNA levels upon Act D treatment.

** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Figure 8 YTHDF3 Mediates FSP1-Regulated Ferroptosis in OS Cells.

(A-D) Knockdown of YTHDF3 suppresses mRNA and protein levels of YTHDF3, GPX4, and FSP1, while FSP1 overexpression rescues GPX4 and FSP1 expression. (E) sh-YTHDF3 inhibits proliferation and induces apoptosis, which is reversed by FSP1 overexpression. (F) Quantification of apoptotic cells. (G-K) FSP1 overexpression


attenuates accumulation of MDA, ROS, Fe²⁺, and Fe³⁺ induced by sh-YTHDF3. (I) FSP1 overexpression restores mitochondrial membrane potential ($\Delta\Psi_m$). (L) Transmission electron microscopy images show mitochondrial morphology (yellow arrows) and chromatin condensation (white arrows). (M-N) sh-YTHDF3 inhibits CoQ10 and NADPH levels, which are rescued by FSP1 overexpression.








** $P < 0.01$, **** $P < 0.0001$

Figure 9 Implications of YTHDF3 in Regulating FSP1-CoQ10-NADPH Axis and Ferroptosis.

(A) Histopathological analysis of sh-YTHDF3 U2OS cell xenografts in mice, revealing altered tumor pathology compared to the control group. (B-E) Immunohistochemical staining illustrating YTHDF3 knockdown's impact on YTHDF3, GPX4, and FSP1 expression in tumor tissues. (F-I) qRT-PCR and Western blot analyses confirming YTHDF3 knockdown's influence on FSP1 and GPX4 mRNA and protein levels in tumor samples. (J-O) Quantification of MDA, ROS, Fe²⁺, Fe³⁺, CoQ10, and NADPH levels in tumor tissue post YTHDF3 knockdown.


*** $P < 0.001$, **** $P < 0.0001$






Preprint


A




B




C




D




E




F



G




H




Preprint


A




B




C






D




E




F




G





H








I











Preprint

